aid. Those same active ingredients were later utilized several years later in the product Tylenol PM. 1998: Excedrin Migraine – At the beginning of 1998, the FDA granted clearance to market Excedrin Migraine for the relief of migraine headache pain and associated symptoms. Excedrin Migraine continued the trend of marketing pain products for specific types of pain, becoming the first migraine headache medication available to consumers without a prescription, even though it has identical active ingredients to the regular Excedrin Extra Strength product, 250 mg acetaminophen, 250 mg aspirin, and 65 mg caffeine. In fact, upon the product's launch, its advertising slogan was “Excedrin is now Excedrin Migraine,” noting that the two were the same product. 2003: Excedrin Tension Headache contains 500 mg acetaminophen, and 65 mg caffeine. 2005: Excedrin Sinus Headache contains 325 mg acetaminophen and 5 mg phenylephrine HCl as a decongestant. 2007: Excedrin Back and Body – a dual-ingredient formula claiming that it "works two ways—as a pain reliever and a pain blocker right where it hurts". Contains 250 mg acetaminophen, 250 mg aspirin. Discontinued – Excedrin Menstrual Complete, which continues the trend of marketing pain products for specific types of pain, even though it has identical active ingredients to the regular Excedrin Extra Strength product and Excedrin Migraine: 250 mg acetaminophen, 250 mg aspirin and 65 mg caffeine. Canada Excedrin is no longer sold in Canada. Previously, Excedrin Migraine and Excedrin Extra Strength sold in Canada had a different formulation compared to the US. In Canada the product sold with those names contained 500 mg of acetaminophen and 65 mg of caffeine per tablet. The reason was that the combination of acetaminophen with aspirin creates the risk of renal papillary necrosis if large doses are taken chronically. Ownership In 2005, Bristol-Myers Squibb announced the sale of its North American consumer medicine business (including Excedrin, Comtrex and Keri brands) to Novartis for $660 million, in order to focus on drugs for the ten most profitable disease areas. As of March 2015, GlaxoSmithKline held majority ownership through a joint venture transaction with Novartis. Recall and production stoppage 2012 recall On January 9, 2012, Novartis announced that it was voluntarily recalling all lots of select bottle-packaging configurations of Excedrin products with expiration dates of December 20, 2014, or earlier as a precautionary measure because the products may contain stray tablets, capsules, or caplets from other Novartis products, or contain